This announcement is a separate document:
聖諾醫藥-B：自願性公告 - Sirnaomics宣佈基於GalNAc RNAi療法藥物STP122G用於抗凝治療的I期臨床試驗第二序列圓滿完成並公佈了中期數據
SIRNAOMICS-B: VOLUNTARY ANNOUNCEMENT - SIRNAOMICS ANNOUNCES INTERIM RESULTS FOR SUCCESSFULCOMPLETION OF THE SECOND COHORT OF PHASE I CLINICALSTUDY OF GALNAC-BASED RNAi THERAPEUTIC STP122G FORANTICOAGULANT THERAPEUTICS
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.